TB-500 | Clinician-Reviewed Peptide Therapy

What happens next

A calm, online process

Treatment availability depends on eligibility and clinician review. Nothing on this page guarantees prescribing, approval, or specific outcomes.

Complete your intake

A short intake captures the context your provider needs to review your file.

Clinician chart review

A licensed clinician reviews your information and approves, requests more, or declines treatment.

Discreet fulfillment

When prescribed, fulfillment is handled through the partnered pharmacy with discreet packaging.

Treatment is determined by a licensed clinician after review. Not all patients are candidates. Individual results vary.

About TB-500

What it is, how it works, what it's studied for, and safety considerations.

TB-500 is a synthetic peptide commonly described as a fragment related to thymosin beta-4. This page is educational and not medical advice.

Last updated: July 2, 2026

What Is TB-500?

TB-500 is commonly described as a synthetic fragment related to thymosin beta-4, a naturally occurring peptide involved in actin binding, cell migration, angiogenesis, and tissue-repair signaling. It is not FDA-approved for human therapeutic use.

How It Works

TB-500-related claims are often based on thymosin beta-4 biology and preclinical wound-healing/tissue-repair research. TB-500 should not be presented as equivalent to all thymosin beta-4 clinical research; claims remain cautious and its mechanism is not an established human clinical effect.

What It’s Studied For

Thymosin beta-4 has published research in wound healing, tissue repair, angiogenesis, inflammation resolution, and dermal healing; TB-500 itself has limited human data, and current orthopedic and wellness claims are often extrapolated from preclinical or related-peptide studies. It is not FDA-approved for these uses.

Regulatory Status

TB-500-related substances have been part of FDA compounding-safety discussions (immunogenicity and peptide-impurity concerns), and TB-500 is prohibited for athletes under the WADA framework. Compounding availability is subject to that status.

What to Expect

Use is provider-directed only; no outcome or timeline is promised, and it does not replace standard care for injury.

Preferred Starting Options / Dosing Notes

Many patients begin with a lower starting option so a licensed clinician can evaluate tolerance, medical history, goals, and safety factors before any adjustments are considered. The starting option shown below is informational and reflects available program data, not self-directed dosing instructions. Final medication, dose, frequency, and treatment plan are determined by a licensed clinician.

Average starting option

10 mg

Available options

10 mg

Provider note: Do not change dose, frequency, or route of use unless directed by your clinician.

Safety Considerations

Human exposure data are limited and long-term risk unknown.
Possible concerns include injection-site and immune reactions and sterility/purity issues.
No peptide is "safe" without qualification.

Important note

Some treatments may involve compounded medications when prescribed by a clinician. Compounded medications are not FDA-approved. The FDA does not evaluate compounded medications for safety, effectiveness, or quality before marketing.

Who Is Not a Candidate

A clinician reviews injury history, recovery goals, medications, immune status, pregnancy status, and cancer history, and whether standard care has been addressed, before considering TB-500.

How It Compares

Both are marketed for recovery but are different molecules with different proposed mechanisms; both are preclinical-evidence-dominant and not FDA-approved.

Frequently Asked Questions

Is TB-500 FDA-approved or WADA-banned?

Not FDA-approved for human therapeutic use, and prohibited for athletes under WADA.

How does it work?

Claims are based largely on thymosin beta-4 biology; TB-500's own human evidence is limited.

What is TB-500 used for?

It is discussed for recovery/tissue repair, but human clinical evidence is limited.

TB-500 vs BPC-157?

Different molecules and mechanisms; both preclinical-dominant and not FDA-approved.

Does payment guarantee a prescription?

No — a licensed clinician decides.

References

Peer-reviewed literature on thymosin beta-4 and TB-500 (PubMed)
FDA compounding-safety communications
WADA Prohibited List

Disclaimer

Although the information on this page is based on available educational research and product information, it is provided for informational purposes only and is not medical advice. Treatment decisions, medication selection, dosing, and eligibility are determined by a licensed clinician after review. Not all patients are candidates, and individual results may vary. Use medications only as directed by your clinician.

Learn more about TB-500

Important safety information

This page is informational and does not replace medical advice from a licensed professional. Treatment availability depends on eligibility, clinician review, and applicable requirements. ElliotMeds does not provide emergency medical services — if you are experiencing a medical emergency, call 911 or go to the nearest emergency room.